VVT Med Establishes Exclusive Canadian Commercial Partnership with CHS for ScleroSafe®

Partnership Expands VVT Med’s Global Commercial Network and Supports the Introduction of ScleroSafe into the Canadian Market

VANCOUVER, BC, Oct. 1, 2026 /CNW/ — VVT Med Inc. (TSXV: VVTM) (“VVT Med” or the “Company”), a medical technology company focused on minimally invasive treatments for venous disease, today announced that CHS Ltd., one of Canada’s established medical technology organizations, has selected ScleroSafe® as the latest addition to its vascular portfolio and entered into an exclusive commercialization agreement dated September 30, 2026, to support the introduction of the technology in Canada.

The agreement establishes a long-term commercial collaboration under which the parties will work together on annual commercial growth plans, physician education, clinical support, market development initiatives and launch preparation for ScleroSafe in Canada. As part of the collaboration, VVT Med intends to pursue the applicable regulatory process required to support commercial introduction in Canada. The agreement will become effective upon receipt of the applicable Health Canada authorization for ScleroSafe and has an initial term of five years, subject to earlier termination in accordance with its terms.

Founded in 1967, CHS provides nationwide commercialization, sales, clinical support and distribution services for medical technologies across Canada. The company operates four distribution centres and can reach approximately 84% of Canadian customers within 48 hours¹. CHS serves hospitals, ambulatory surgical centres and healthcare providers across a broad range of specialties, including vascular and interventional care.

Canada represents an important strategic market as VVT Med continues to expand the global commercialization of ScleroSafe. The partnership establishes the Company’s commercial platform in the jurisdiction where its shares are publicly listed while advancing its strategy of collaborating with experienced regional partners to support long-term market development.

“Our strategy is to partner with organizations that can successfully develop markets, not simply distribute products,” said Erez Tetro, Chief Executive Officer of VVT Med. “CHS brings nearly six decades of commercial experience, an established national infrastructure and trusted relationships throughout the Canadian healthcare system Together, we believe we have a strong foundation to introduce ScleroSafe to Canadian physicians and support broader market adoption over time.”

“At CHS, we seek partnerships that bring meaningful innovation to Canadian healthcare providers,” said Tim Valters, Chief Executive Officer of Canadian Hospital Specialties. “We believe ScleroSafe is an innovative addition to our vascular portfolio and aligns with our commitment to delivering differentiated medical technologies supported by clinical education and customer service. We look forward to working with the VVT Med team to support the introduction of this technology to physicians across Canada.”

ScleroSafe is VVT Med’s proprietary minimally invasive, non-thermal, non-tumescent (NT-NT) technology for the treatment of incompetent veins and has received U.S. FDA 510(k) clearance together with regulatory approvals in multiple international markets.

Building on its expanding international commercial activities, VVT Med continues to receive recurring orders in a number of markets where ScleroSafe has been commercialized The Company believes these repeat orders reflect continued customer engagement and support its strategy of expanding through established regional distribution partners.

About Canadian Hospital Specialties

CHS Ltd. founded in 1967, is a Canadian medical technology company specializing in the commercialization, manufacturing and distribution of medical technologies across Canada.

About VVT Med

VVT Med develops and commercializes minimally invasive technologies for the treatment of venous disease. Its flagship product, ScleroSafe®, is a non-thermal, non-tumescent technology designed to provide physicians with an innovative treatment option for incompetent veins.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this news release include, but are not limited to, statements regarding the effectiveness and anticipated benefits of the commercialization agreement with CHS, the receipt of applicable regulatory approvals in Canada, the anticipated introduction and commercialization of ScleroSafe in Canada, physician education and market development initiatives, future customer orders, market adoption of ScleroSafe, and the Company’s broader international commercialization strategy.

Forward-looking statements are based on a number of assumptions believed by mangement to be reasonable as of the date of this news release, including assumptions regarding the receipt of required regulatory approvals, the ability of the parties to successfully implement their commercialization plans, continued demand for venous disease treatment products, and general business and economic conditions.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the risk that required regulatory approvals are not obtained in a timely manner or at all, risks relating to commercialization efforts and market acceptance of ScleroSafe, the ability of CHS and the Company to successfully execute their respective obligations under the agreement, competitive developments, changes in healthcare market conditions, and the other risks described in the Company’s public disclosure documents.

Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are made as of the date of this news release and the Company undertakes no obligation to update or revise any such statements except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE VVT MED INC.